InMode因“引人注目”的风险/回报前景而在BTIG进行新收购

2024-10-18 00:58

BTIG has initiated coverage of InMode (NASDAQ:INMD) at buy saying that while the stock is trading at 4-year lows, it has a strong revenue CAGR and has a "compelling" risk/reward setup.
The firm set a $25 price target (~48% upside).
BTIG analysts noted that despite ~38% revenue CAGR from 2018-2023), the aesthetic medical devices manufacturer is trading at multi-year lows due to lower demand for aesthetic capital equipment and procedures over the last few quarters, which the firm attributes to macroeconomic uncertainty.
The firm added it sees several ways InMode can return to growth once the macroeconomic environment improves.
"BTIG spoke with an early adopter of the recently launched IgniteRF platform who said high-volume providers will be the first to adopt/ upgrade to the new system given significant clinical enhancements and time-savings," a recent note reads. "Additionally, markets outside the U.S. still represent a large and growing opportunity for medical aesthetics while adoption of adjacent platform technologies in gynecology and ophthalmology remain in the early innings."

More on InMode